《Seminars In Cancer Biology》雜志的最新年發文量為83篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在腫瘤學領域的學術影響力。
該刊聚焦于醫學-腫瘤學領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 較慢,6-12周 約15.1周。
Seminars In Cancer Biology 雜志發文統計
文章名稱引用次數
- Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy115
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer63
- CircRNAs and cancer: Biomarkers and master regulators54
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics50
- Glioma epigenetics: From subclassification to novel treatment options50
- Prognostic and predictive biomarkers in breast cancer: Past, present and future47
- PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux46
- Emerging targets in cancer immunotherapy45
- Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments40
- Therapy resistance mediated by cancer stem cells39
國家/地區發文量
- USA145
- CHINA MAINLAND51
- Italy44
- GERMANY (FED REP GER)37
- India34
- England27
- Spain20
- Saudi Arabia19
- Belgium18
- Australia16
